Skip to content

"Glargine insulin efficacy in Cystic Fibrosis patients with glucose intolerance and clinical deterioration"

"Glargine insulin efficacy in Cystic Fibrosis patients with glucose intolerance and clinical deterioration"

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2005-002135-27-IT
Enrollment
Unknown
Registered
2005-06-28
Start date
2005-07-06
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystic Fibrosis patients with glucose intolerance MedDRA version: 6.1 Level: PT Classification code 10011762

Interventions

Trade Name: LANTUS*SC 5CAR3ML100UI/ML Product Name: NA Product Code: NA Pharmaceutical Form: Solution for injection INN or Proposed INN: Insulin glargine Concentration unit: IU international unit(s)

Sponsors

ISTITUTO GIANNINA GASLINI
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? yes Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026